TRVI
HealthcareTrevi Therapeutics, Inc. · Biotechnology · $2B
What is Trevi Therapeutics, Inc.?
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious neurologically mediated conditions. Its pipeline centers on a single investigational asset, Haduvio, currently advancing through late-stage clinical trials.
Trevi Therapeutics is working to bring Haduvio — an oral extended-release formulation of nalbuphine — to patients suffering from conditions such as chronic pruritus and chronic cough associated with idiopathic pulmonary fibrosis. The company operates under a license agreement with Endo Pharmaceuticals to develop and commercialize nalbuphine hydrochloride-based products. As a clinical-stage company, Trevi does not yet generate product revenue and depends on trial outcomes and eventual regulatory approval to reach commercialization.
Trevi Therapeutics was incorporated in 2019 and is headquartered in New Haven, Connecticut.
- Haduvio — oral extended-release nalbuphine formulation
- Phase IIb/III program for chronic pruritus
- Clinical program for chronic cough in idiopathic pulmonary fibrosis patients
- Nalbuphine hydrochloride license platform via Endo Pharmaceuticals
Is TRVI a Good Stock to Buy?
UQS Score rates TRVI as Poor overall, reflecting the early-stage nature and elevated uncertainty of its clinical pipeline.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company's balance sheet or near-term financial exposure is more contained than its overall profile might imply. This is not uncommon for clinical-stage biotechs that have managed cash burn carefully.
Quality, Moat, and Growth all register as Weak, consistent with a pre-revenue company that has no approved products, no durable competitive advantages yet established, and limited near-term revenue visibility. Valuation is rated Elevated, meaning the current market price appears to price in optimistic outcomes.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does TRVI pay dividends?
No — Trevi Therapeutics, Inc. does not currently pay a dividend.
Trevi Therapeutics does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. All available capital is directed toward funding clinical trials and advancing Haduvio toward potential regulatory approval. Income-focused investors should look elsewhere; TRVI is a pure pipeline story.
When does TRVI report earnings?
Trevi Therapeutics reports financial results on a quarterly cadence, standard for US-listed public companies.
As a pre-revenue clinical-stage company, quarterly reports focus primarily on cash runway, operating expenses, and trial progress updates rather than traditional revenue or profit metrics. Pipeline milestones tend to drive more market reaction than the income statement.
For the most recent quarter's results and trial updates, visit Trevi Therapeutics' investor relations page directly.
TRVI Price History
+586.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Trevi Therapeutics, Inc.?
Based on Trevi Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
TRVI Long-term Outlook
The fundamental outlook for TRVI is binary in nature — heavily dependent on clinical trial readouts for Haduvio. The Growth pillar is rated Weak, reflecting the absence of near-term revenue and the long path from trial to commercialization. The Risk pillar rating of Good provides some reassurance about financial stability in the near term, but the Elevated Valuation rating suggests the market may already be pricing in favorable trial outcomes, leaving limited margin for error if data disappoint.
Growth drivers
- Positive Phase IIb/III data readouts for Haduvio in chronic pruritus or chronic cough
- Potential regulatory approval opening a first-mover position in underserved neurologically mediated conditions
- Expanded pipeline applications for the nalbuphine platform under the Endo Pharmaceuticals license
Key risks
- Clinical trial failure or unfavorable data could significantly impair the company's value
- Elevated Valuation rating suggests limited upside buffer if trial timelines slip
- Pre-revenue status means continued dependence on capital markets to fund operations
TRVI vs Peers
Trevi Therapeutics operates in a competitive clinical-stage biotech landscape alongside other specialty and rare-disease focused companies.
Sionna focuses on cystic fibrosis treatments, pursuing a different disease area with its own distinct clinical and regulatory pathway.
AnaptysBio targets inflammatory diseases through antibody-based therapies, giving it a different mechanism of action and pipeline profile compared to Trevi's nalbuphine platform.
BioCryst has an approved commercial product on the market, placing it at a more advanced stage of development than Trevi's purely clinical pipeline.
Frequently Asked Questions
What does Trevi Therapeutics do?
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release formulation of nalbuphine, to treat serious neurologically mediated conditions including chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis. The company has not yet commercialized any products.
Does TRVI pay dividends?
No, Trevi Therapeutics does not pay a dividend. As a pre-revenue clinical-stage company, it reinvests all available capital into advancing its clinical programs. Dividend income is not part of the TRVI investment thesis at this stage.
When does TRVI report earnings?
Trevi Therapeutics follows a standard quarterly reporting cadence for US-listed companies. Because it is pre-revenue, reports focus on cash position and trial updates rather than traditional earnings. Check the company's investor relations page for the latest schedule.
Is TRVI a good stock to buy?
UQS Score rates TRVI as Poor overall, driven by Weak ratings across Quality, Moat, and Growth pillars, alongside an Elevated Valuation. The Risk pillar is the relative standout. Whether TRVI fits a portfolio depends on an investor's risk tolerance and view on clinical trial outcomes. See the full breakdown on UQS Score.
Is TRVI overvalued?
The UQS Valuation pillar for TRVI is rated Elevated, suggesting the current market price may already reflect optimistic assumptions about Haduvio's clinical and commercial success. Investors should weigh this against the binary risk of a clinical-stage pipeline.
How does TRVI compare to its competitors?
Compared to peers like BioCryst Pharmaceuticals, which has an approved commercial product, Trevi remains earlier in its development journey. AnaptysBio and Sionna Therapeutics pursue different disease areas and mechanisms, making direct comparisons difficult. UQS Score's competitor view provides a structured quality comparison across these names.
What is TRVI's market cap bracket?
Trevi Therapeutics is classified as a small-cap company. This is typical for clinical-stage biotechs whose market value reflects pipeline potential rather than current revenues or earnings.
Who founded Trevi Therapeutics?
Founding details for Trevi Therapeutics are publicly available through the company's official disclosures and investor relations materials. The company was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Is TRVI a long-term quality investment?
As a long-term quality indicator, TRVI's Poor UQS Score reflects meaningful structural challenges — weak fundamentals, no established moat, and an Elevated Valuation. Long-term quality investors typically look for companies with durable competitive advantages and consistent financial performance, which TRVI has not yet demonstrated.
What is the main competitive advantage of Trevi Therapeutics?
Trevi's potential advantage lies in its licensed nalbuphine platform and its focus on underserved neurologically mediated conditions where few approved treatments exist. However, the UQS Moat pillar is rated Weak, reflecting that no durable competitive advantage has been established ahead of regulatory approval.
What sector does TRVI belong to?
Trevi Therapeutics operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Investors can explore other [healthcare sector stocks](/sector/healthcare) on UQS Score to compare quality profiles across the industry.
Is TRVI a growth stock or value stock?
Based on UQS pillar labels, TRVI does not fit neatly into either category. Its Growth pillar is rated Weak given the pre-revenue stage, and its Valuation pillar is Elevated rather than attractive. It is best characterized as a speculative clinical-stage biotech rather than a traditional growth or value play.
Unlock Full TRVI Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access underlying financial metrics driving each pillar
- ✓Compare TRVI against peers on a standardized quality framework
- ✓Track pillar changes as new clinical and financial data emerge
- ✓Screen for higher-quality healthcare stocks using UQS filters
Pro Analysis
TRVI — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | 15.9 | 0.0 | 6.0 | 18.5 | 71.4 | 0.0 | -0.9 |
| Apr 14, 2026 | 16.8 | 0.0 | 6.0 | 23.1 | 71.4 | 0.0 | -11.0 |
| Apr 13, 2026 | 27.8 | 0.0 | 50.0 | 23.1 | 71.4 | 0.0 | +11.0 |
| Apr 2, 2026 | 16.8 | 0.0 | 6.0 | 23.1 | 71.4 | 0.0 | — |
TRVI — Pillar Breakdown
Quality
— 0.0/100 (25%)Trevi Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)Trevi Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 71.5/100 (15%)Trevi Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Trevi Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 6/100 (25%)Trevi Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TRVI.
Score Composition
Financial Data
More Stock Analysis
How is the TRVI UQS Score Calculated?
The UQS (Unified Quality Score) for Trevi Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Trevi Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Trevi Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.